Every 15 minutes, someone in the U.S. dies of a drug-resistant superbug. A few decades from now, antibiotic-resistant bacterial infections threaten to become the leading cause of death worldwide, outpacing cancer.
In the race for a solution to the antibiotic resistance crisis, a century-old practice is attracting renewed interest. The treatment, called phage therapy, involves co-opting friendly viruses that kill bacteria but ignore human cells.
Bacteria can — and do — develop resistance to phages, just as they do with antibiotics. But unlike antibiotics, phages can evolve counter defenses of their own.
Now, researchers at Michigan State University have identified a counter defense used by a group of phages common in the human gut, called Enterobacteria phage T2, that helps them stay one step ahead of their bacterial hosts.
These phages have mutation hotspots scattered throughout their genomes that help them modify key defense genes, the researchers report.